Evidence map›Paper›PMID 39199170›Full record

ArticleAntioxidants (Basel, Switzerland)2024

Transcriptional Dynamics of NRF2 Overexpression and KEAP1-NRF2 Inhibitors in Human Cell Line and Primary Lung Cells.

Corinne Hamblet, Karin Björhall, Susann Busch, Ulf Gehrmann, Lisa Öberg, Rebekka Kubisch-Dohmen, Sonja Haas, Manish K Aneja, Johannes Geiger, Carsten Rudolph and 1 more

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Corinne HambletBioscience Chronic Obstructive Pulmonary Disease & Idiopathic Pulmonary Fibrosis, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.
Karin BjörhallBioscience Chronic Obstructive Pulmonary Disease & Idiopathic Pulmonary Fibrosis, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.
Susann BuschRespiratory & Immunology, Neuroscience, Vaccines and Immune Therapies Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 431 83 Mölndal, Sweden.
Ulf GehrmannTranslational Science and Experimental Medicine Research, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.
Lisa ÖbergTranslational Science and Experimental Medicine Research, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.ORCID 0000-0001-7127-1711
Rebekka Kubisch-DohmenETHRIS GmbH, 82152 Planegg, Germany.ORCID 0000-0002-5555-6941
Sonja HaasETHRIS GmbH, 82152 Planegg, Germany.
Manish K AnejaETHRIS GmbH, 82152 Planegg, Germany.
Johannes GeigerETHRIS GmbH, 82152 Planegg, Germany.
Carsten RudolphETHRIS GmbH, 82152 Planegg, Germany.
Ellinor HornbergProjects and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress in the human lung is caused by both internal (e.g., inflammation) and external stressors (smoking, pollution, and infection) to drive pathology in a number of lung diseases. Cellular damage caused by oxidative damage is reversed by several pathways, one of which is the antioxidant response. This response is regulated by the transcriptional factor NRF2, which has the ability to regulate the transcription of more than 250 genes. In disease, this balance is overwhelmed, and the cells are unable to return to homeostasis. Several pharmacological approaches aim to improve the antioxidant capacity by inhibiting the interaction of NRF2 with its key cytosolic inhibitor, KEAP1. Here, we evaluate an alternative approach by overexpressing NRF2 from chemically modified RNAs (cmRNAs). Our results demonstrate successful expression of functional NRF2 protein in human cell lines and primary cells. We establish a kinetic transcriptomic profile to compare antioxidant response gene expression after treatment of primary human bronchial epithelial cells with either KEAP1 inhibitors or cmRNAs. The key gene signature is then applied to primary human lung fibroblasts and alveolar macrophages to uncover transcriptional preferences in each cell system. This study provides a foundation for the understanding of NRF2 dynamics in the human lung and provides initial evidence of alternative ways for pharmacological interference.

Indexed as

antioxidant responsecmRNAKEAP1lungNRF2

Identifiers

PMID39199170
PMCPMC11351141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.